Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study


ARTAÇ M., COŞKUN H. Ş., Korkmaz L., Kocer M., Turhal N. S., ENGİN H., ...More

CLINICAL GENITOURINARY CANCER, vol.14, no.4, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 4
  • Publication Date: 2016
  • Doi Number: 10.1016/j.clgc.2016.04.021
  • Journal Name: CLINICAL GENITOURINARY CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Süleyman Demirel University Affiliated: Yes

Abstract

Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.